Physician profile
Robert J Hally
NPI 1629123096
$5,191.77
in general payments reported to CMS, 2019-2025
31 companies · $832 in 2025
The $832 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $900 · 2020: $554 · 2021: $707 · 2022: $1,234 · 2023: $446 · 2024: $519 · 2025: $832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,796.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,600.79 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $821.53 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $546.80 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Pfizer INC. | $331.90 | 2019-2025 | |
| Janssen Biotech, INC. | $264.15 | 2019-2025 | Tremfya, Stelara |
| Celgene Corporation | $252.06 | 2022-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $190.94 | 2020-2025 | Rebyota |
| Gilead Sciences, INC. | $188.35 | 2019-2024 | |
| Genzyme Corporation | $140.42 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $77.56 | 2023-2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $74.88 | 2025 | Iqirvo |
| Qol Medical, LLC | $74.88 | 2023-2024 | Sucraid, Sucraid |
| Romark Laboratories, Lc | $72.80 | 2020 | |
| Medtronic, INC. | $60.65 | 2022-2025 | Pillcam |
| Daiichi Sankyo INC. | $51.23 | 2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $49.52 | 2021-2024 | Sutab, Suflave |
| Lilly USA, LLC | $46.72 | 2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $42.15 | 2020 | |
| Ironwood Pharmaceuticals, INC | $39.78 | 2021-2024 | |
| Shionogi INC | $34.12 | 2019 | |
| Stryker Corporation | $33.12 | 2025 | Neptune |
| Redhill Biopharma INC. | $30.61 | 2020-2021 | |
| Vivus LLC | $26.69 | 2019-2025 | Qsymia |
| Novo Nordisk INC | $20.93 | 2025 | Wegovy |
| Vibrant Gastro, INC. | $20.66 | 2024 | Vibrant Starter Kit |
| E.R. Squibb & Sons, L.L.C. | $19.53 | 2022 | |
| Ardelyx, INC. | $18.43 | 2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $16.99 | 2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $15.31 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $14.22 | 2019 | |
| Alfasigma USA, INC. | $14.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hally listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.